Cellectis SA (CLLS)

28.54
0.40 1.38
NASDAQ : Health Technology
Prev Close 28.94
Open 28.62
Day Low/High 28.28 / 29.15
52 Wk Low/High 21.25 / 38.85
Volume 197.60K
Avg Volume 318.70K
Exchange NASDAQ
Shares Outstanding 41.60M
Market Cap 1.23B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cellectis And Allogene Therapeutics Intend To Continue Strategic Cancer Immunotherapy Collaboration To Accelerate Development And Commercialization Of Allogeneic Off-the-Shelf CAR T Therapies

Cellectis And Allogene Therapeutics Intend To Continue Strategic Cancer Immunotherapy Collaboration To Accelerate Development And Commercialization Of Allogeneic Off-the-Shelf CAR T Therapies

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic...

Dr. Mathieu Simon To Retire As Cellectis' Chief Operating Officer; Elsy Boglioli Named As Successor

Dr. Mathieu Simon To Retire As Cellectis' Chief Operating Officer; Elsy Boglioli Named As Successor

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...

Cellectis Reports 4th Quarter And Full Year 2017 Financial Results

Cellectis Reports 4th Quarter And Full Year 2017 Financial Results

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...

Cellectis: Servier And Pfizer Announce Results Of UCART19 First-in-Human Trials To Be Presented At The 44th EBMT (European Society For Blood And Marrow Transplantation) Annual Meeting

Cellectis: Servier And Pfizer Announce Results Of UCART19 First-in-Human Trials To Be Presented At The 44th EBMT (European Society For Blood And Marrow Transplantation) Annual Meeting

Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), today announced that results from the two phase 1 trials with UCART19, the...

Two Issued U.S. Patents Granted To Cellectis For CRISPR Use In T-Cells

Two Issued U.S. Patents Granted To Cellectis For CRISPR Use In T-Cells

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today...

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

Cellectis To Present At The 36th Annual J.P. Morgan Healthcare Conference On Monday, January 8, 2018 At 12:00 P.M. PT

Cellectis To Present At The 36th Annual J.P. Morgan Healthcare Conference On Monday, January 8, 2018 At 12:00 P.M. PT

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic...

Preliminary Data From Servier And Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult And Pediatric Acute Lymphoblastic Leukemia Trials

Preliminary Data From Servier And Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult And Pediatric Acute Lymphoblastic Leukemia Trials

Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS) presented at the 59th American Society of Hematology (ASH) Annual...

Cellectis Appoints Elsy Boglioli To Executive Vice President, Strategy And Corporate Development

Cellectis Appoints Elsy Boglioli To Executive Vice President, Strategy And Corporate Development

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

Cellectis Appoints Immuno-Oncology Leader Stéphane Depil To Position Of Senior Vice President Research & Development And Chief Medical Officer

Cellectis Appoints Immuno-Oncology Leader Stéphane Depil To Position Of Senior Vice President Research & Development And Chief Medical Officer

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

Cellectis Demonstrates Fine And Predictable Tuning Of TALEN® Gene Editing Targeting To Improve T-cell Adoptive Immunotherapy

Cellectis Demonstrates Fine And Predictable Tuning Of TALEN® Gene Editing Targeting To Improve T-cell Adoptive Immunotherapy

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic...

Cellectis Reports Financial Results For Third Quarter And First Nine Months Of 2017

Cellectis Reports Financial Results For Third Quarter And First Nine Months Of 2017

Regulatory News: Cellectis S.A.

FDA Lifts Clinical Hold On Cellectis Phase 1 Clinical Trials With UCART123 In AML And BPDCN

FDA Lifts Clinical Hold On Cellectis Phase 1 Clinical Trials With UCART123 In AML And BPDCN

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells...

First Week of December 15th Options Trading For Cellectis (CLLS)

First Week of December 15th Options Trading For Cellectis (CLLS)

Investors in Cellectis SA saw new options begin trading this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLLS options chain for the new December 15th contracts and identified one put and one call contract of particular interest.

Cellectis Announces Two Oral Presentations And One Poster Presentation At The 2017 ASH Annual Meeting

Cellectis Announces Two Oral Presentations And One Poster Presentation At The 2017 ASH Annual Meeting

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

Servier And Pfizer Announce Preliminary Results Of The First-in-Human Trials Of UCART19 Will Be Presented At The 59th American Society Of Hematology (ASH) Annual Meeting

Servier And Pfizer Announce Preliminary Results Of The First-in-Human Trials Of UCART19 Will Be Presented At The 59th American Society Of Hematology (ASH) Annual Meeting

Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), today announced that preliminary results from two phase 1 trials with UCART19,...

Mathieu Simon, M.D. Cellectis' EVP & Chief Operating Officer, To Serve As Interim Chief Medical Officer

Mathieu Simon, M.D. Cellectis' EVP & Chief Operating Officer, To Serve As Interim Chief Medical Officer

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Cellectis S.A.

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Cellectis S.A.

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.

Cellectis To Participate In Upcoming Investor Conferences

Cellectis To Participate In Upcoming Investor Conferences

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several...

Cellectis Reports Clinical Hold Of UCART123 Studies

Cellectis Reports Clinical Hold Of UCART123 Studies

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today having...

Cellectis' UCART123 Administered To First Patient With BPDCN In Phase I Clinical Trial At MD Anderson Cancer Center

Cellectis' UCART123 Administered To First Patient With BPDCN In Phase I Clinical Trial At MD Anderson Cancer Center

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells...

Relative Strength Alert For Cellectis

Relative Strength Alert For Cellectis

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cellectis Reports Financial Results For 2nd Quarter And First Six Months 2017

Cellectis Reports Financial Results For 2nd Quarter And First Six Months 2017

Regulatory News: Cellectis S.A.

Cellectis Granted Patent For CRISPR Use In T-Cells

Cellectis Granted Patent For CRISPR Use In T-Cells

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells...

TheStreet Quant Rating: D (Sell)